Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review
Authors' conclusion
Our SLR, the first to summarize management and outcomes of ASS-ILD, found no conclusive difference between effectiveness of treatments.
Study context
- Population
- Patients with interstitial lung disease (ILD) associated with anti-synthetase syndrome (ASS-ILD); articles published 1946-September 202310 articles
- Participants
- 514 patients
- Comparison
- Rituximab vs CYC
- Outcome
- Post-treatment change in pulmonary function tests (FVC, DLCO)
- Follow-up
- 1 year
Methodological detailsrandom effects model, paired t-tests
- Random effects model
- Paired t-tests
Pooled result
As reported in the abstract
Pooled improvement from baseline in pulmonary function
Pooled improvement in forced vital capacity (FVC) from baseline (s.e. 3.1); paired t-test P = 0.007
14.1%
Pooled improvement in DLCO (s.e. 2.8); paired t-test P = 0.002
15.1%
Further pooled results
FVC improvement and DLCO increase by treatment · 1 year · value = FVC improvement
DLCO increase
Baseline pulmonary function, pooled estimate
- FVC, % predicted (s.e. 2.1)
- 60.8%
- DLCO (s.e. 3.5)
- 49.8%
Baseline HRCT pattern: non-specific interstitial pneumonia
- NSIP among 447 patients with baseline HRCT (n = 220)
- 49.2%
Autoantibodies
- Anti-Jo1
- 48%
- Associated anti-Ro52
- 27.8%
Deaths
- Deaths reported
- 28
Original publication
Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review. Rheumatology (Oxford). Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →